Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 70518-4392

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 70518-4392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Donepezil Hydrochloride 5 mg film-coated tablets in a quantity of 90. The label identifies the product as Donepezil HCl Tablet with NDC 70518-4392-00. It is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer is Rising Pharma Inc., Allendale, NJ. The label includes storage instructions, dosage notice to see insert, and safety warnings to keep out of children's reach.*

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

A line graph comparing clinical changes over 30 weeks in patients treated with Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo. The vertical axis shows the mean change from baseline in ADAS-cog scores, with clinical improvement above baseline and clinical decline below. Time in weeks is on the horizontal axis. The Donepezil groups show less decline or some improvement compared to placebo, which shows progressive clinical decline over time.*

FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

A line graph showing the cumulative percentage of patients plotted against ADCS-ADL change from baseline. Two curves are depicted: one for Donepezil Hydrochloride 10 mg/day and one for placebo, illustrating patient response distribution with performance changes from baseline on the x-axis and cumulative patient percentage on the y-axis.*

FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

A line graph illustrating SIB (Severe Impairment Battery) change from baseline over 24 weeks of donepezil hydrochloride treatment at doses of 10 mg/day and 23 mg/day. The y-axis shows LS mean change with standard error, marking clinical improvement above baseline and clinical decline below. The x-axis represents weeks of drug treatment, showing higher improvement trends for the 23 mg/day dose compared to 10 mg/day.*

FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

A cumulative percentage of patients chart showing SIB change from baseline for Donepezil Hydrochloride at dosages of 23 mg/day and 10 mg/day. The x-axis represents SIB change from baseline in a range from 50 to -60, and the y-axis shows the cumulative percentage of patients from 0 to 100%. The chart compares two dosage groups using separate lines marked with distinct symbols.*

FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

A bar chart comparing the percentage of patients by CIBIC-plus rating for Donepezil Hydrochloride at dosages of 10 mg/day and 23 mg/day. Ratings include categories from Markedly Improved to Markedly Worse, shown on the horizontal axis, with percentages on the vertical axis.*

FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The (Donepezil Fig2)

A cumulative percentage graph showing patient responses to placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg, plotted against change from baseline in ADAS-cog scores. A table summarizes treatment group data at specific score changes (-7, -4, 0), highlighting percent patient improvements by dosage.*

FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

A bar chart comparing the percentage of patients by CIBIC-plus rating across three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The ratings range from Markedly Improved to Markedly Worse, showing distribution differences in patient outcomes among the three groups.*

FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

A line graph depicting the change from baseline in ADAS-cog scores (mean ± SE) over 12 weeks of drug treatment followed by a placebo period, comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The graph shows trends toward clinical improvement for both donepezil doses versus clinical decline for placebo.*

FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: (Donepezil Fig5)

A cumulative percentage plot showing patients' change from baseline in a clinical measure related to Donepezil Hydrochloride treatment. The graph compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, with a table summarizing percentage changes in ADAS-cog scores for each treatment group.*

FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

A bar graph depicting the distribution of CIBIC-plus ratings by percentage of patients across three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. Ratings range from 'Markedly Improved' to 'Markedly Worse,' illustrating patient response categories for each treatment cohort.*

FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

A line graph depicting the SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis shows mean change from baseline with standard error, highlighting clinical improvement above baseline and clinical decline below. Donepezil shows an increase indicating improvement, while placebo shows a decline.*

FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

A cumulative distribution graph comparing SIB change from baseline between Donepezil Hydrochloride 10 mg/day and placebo. The x-axis shows SIB change from baseline with negative values indicating improvement, and the y-axis shows the cumulative percentage of patients. Two curve lines represent the drug and placebo groups respectively.*

FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis measures change indicating clinical improvement or decline, and the x-axis shows months of treatment. Both groups show decline, with the placebo group declining more.*

FDA Label Image

Chemical Structure (Donepezil Str)

Chemical structure of Donepezil Hydrochloride showing the molecular arrangement of its key components, including methoxy groups and a piperidine ring, along with the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.